Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio5.34
Quick Ratio5.34
Price-To-Earnings
Trailing P/E Ratio-4.96
Forward P/E Ratio-8.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.90 million
Price / Sales49.29
Cash FlowN/A
Price / CashN/A
Book Value$3.03 per share
Price / Book6.29
Profitability
EPS (Most Recent Fiscal Year)($3.84)
Net Income$-14,190,000.00
Net MarginsN/A
Return on Equity-86.30%
Return on Assets-76.75%
Miscellaneous
Employees6
Outstanding Shares7,500,000
Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions
What is Acer Therapeutics' stock symbol?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Acer Therapeutics' earnings last quarter?
Acer Therapeutics Inc (NASDAQ:ACER) released its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.69) by $0.16. View Acer Therapeutics' Earnings History.
What price target have analysts set for ACER?
3 brokers have issued twelve-month price targets for Acer Therapeutics' stock. Their forecasts range from $50.00 to $70.00. On average, they anticipate Acer Therapeutics' share price to reach $60.00 in the next year. View Analyst Ratings for Acer Therapeutics.
Who are some of Acer Therapeutics' key competitors?
Some companies that are related to Acer Therapeutics include Obseva (OBSV), Lannett (LCI), AC Immune (ACIU), Achaogen (AKAO), Cara Therapeutics (CARA), Zymeworks (ZYME), Stemline Therapeutics (STML), TIGENIX/S (TIG), Rigel Pharmaceuticals (RIGL), Aurinia Pharmaceuticals (AUPH), Merus (MRUS), Verastem (VSTM), ZIOPHARM Oncology (ZIOP), Synergy Pharmaceuticals (SGYP) and ArQule (ARQL).
Who are Acer Therapeutics' key executives?
Acer Therapeutics' management team includes the folowing people:
- Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 42)
- Mr. Harry S. Palmin, Chief Financial Officer (Age 48)
- Mr. Jefferson Davis, Acting Chief Bus. Officer (Age 51)
- Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 53)
- Ms. Kim Tharaldsen, Sr. Director of Marketing
Has Acer Therapeutics been receiving favorable news coverage?
Headlines about ACER stock have trended somewhat positive on Thursday, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Acer Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Acer Therapeutics' major shareholders?
Acer Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Heartland Advisors Inc. (0.74%) and Neuberger Berman Group LLC (0.27%). Company insiders that own Acer Therapeutics stock include Steve Aselage and Timothy C Barabe. View Institutional Ownership Trends for Acer Therapeutics.
Which institutional investors are buying Acer Therapeutics stock?
How do I buy shares of Acer Therapeutics?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acer Therapeutics' stock price today?
One share of ACER stock can currently be purchased for approximately $19.06.
How big of a company is Acer Therapeutics?
Acer Therapeutics has a market capitalization of $143.65 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.
How can I contact Acer Therapeutics?
Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]
MarketBeat Community Rating for Acer Therapeutics (ACER)
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
